Bayer using AI optimize drug discovery, disease diagnosis

Bayer using AI to optimize drug discovery, disease diagnosis

10:47 AM, 10th October 2019
Bayer logo

LEVERKUSEN, GERMANY/READING, UK: Bayer has launched new LifeHub in UK. The hub will accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions.

The new hub is the seventh pillar of Bayer’s global network of LifeHubs designed to accelerate the co-exploration and development of pioneering solutions to solve global challenges in health and nutrition.

As a first step, Bayer’s LifeHub UK will focus on the development of AI-enabled radiology solutions by building on its longstanding knowledge and expertise in the medical imaging field. Clinical AI company Sensyne Health – after sealing a collaboration agreement with Bayer earlier this year – is one of the first companies to move into LifeHub UK. In addition to the already-established collaboration, both parties intend to conduct joint R&D activities for the development of AI-enabled imaging solutions.

Bayer’s network of LifeHubs strives to springboard solutions at the intersection of health and nutrition by exploring promising leads through collaboration with customers and entrepreneurs. As such, the brightest minds within and beyond Bayer are invited to incubate solutions, technologies and pilot new business models through alliances that explore cutting-edge technologies.

“We are delighted to launch LifeHub UK. We firmly believe that artificial intelligence has transformative potential for healthcare which can lead to enhancements in prediction, prevention and personalized treatments,” said Kemal Malik, Bayer Board Member for Innovation.

“Today’s global challenges in health and nutrition are too large for one single companyto tackle alone. This is why our Open Innovation strategy is rooted in a newly-designed global network of LifeHubs which boast offerings from partnering and incubation programs to world-class venturing activities,” added Monika Lessl, Head of Corporate Innovation, R&D and Societal Engagement at Bayer.

© Worldofchemials News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Nouryon introduces new range of demulsifiers for oilfield market

AMSTERDAM, NETHERLANDS: Nouryon has introduced new range of demulsifiers that provide oil producers with a more sustainable option to separate crude o ...

Read more
Equinor bags exploration permit offshore Australia’s northwest shelf

STAVANGER, NORWAY: Equinor has been awarded exploration acreage in the Northern Carnarvon Basin offshore Western Australia. The new exploration permi ...

Read more
Nobel Prize for Chemistry 2019 awarded for work on lithium-ion batteries

STOCKHOLM, SWEDEN: The Nobel Prize in Chemistry 2019 was finally announced. Three scientists were rewarded for their work in the development of the li ...

Read more
AkzoNobel to be official coatings supplier for NYYC American Magic

AMSTERDAM, NETHERLANDS: AkzoNobel said that its Awlgrip brand will be the official coatings supplier for New York Yacht Club’s (NYYC) American M ...

Read more
Lupin gets GMP certificate from Japanese agency

NEW DELHI, INDIA: Homegrown pharma major Lupin said it has received GMP Certificate from Pharmaceutical and Medical Devices Agency, Japan for its Mand ...

Read more
Total starts construction of its third solar power plant in Japan

PARIS, FRANCE/TOKYO, JAPAN: Total Solar International, a wholly owned subsidiary of Total SA, has started the construction of Miyagi Osato Solar Park, ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X